Lumosa Therapeutics Co., Ltd. (TPEX:6535)
161.50
+2.50 (1.57%)
May 13, 2025, 1:30 PM CST
Lumosa Therapeutics Revenue
Lumosa Therapeutics had revenue of 8.90M TWD in the quarter ending March 31, 2025, with 99.33% growth. This brings the company's revenue in the last twelve months to 43.59M, down -18.38% year-over-year. In the year 2024, Lumosa Therapeutics had annual revenue of 39.15M, down -31.21%.
Revenue (ttm)
43.59M
Revenue Growth
-18.38%
P/S Ratio
625.80
Revenue / Employee
1.01M
Employees
43
Market Cap
27.28B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 39.15M | -17.76M | -31.21% |
Dec 31, 2023 | 56.92M | 30.27M | 113.63% |
Dec 31, 2022 | 26.64M | 9.28M | 53.45% |
Dec 31, 2021 | 17.36M | -4.29M | -19.81% |
Dec 31, 2020 | 21.65M | -150.39M | -87.42% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PharmaEssentia | 11.34B |
Caliway Biopharmaceuticals | 40.47M |
Bora Pharmaceuticals Co., LTD. | 19.25B |
Lotus Pharmaceutical | 19.12B |
Polaris Group | 107.00M |
Oneness Biotech | 117.33M |
Pegavision | 6.69B |
Center Laboratories | 1.63B |